Αρχική World News EMA Recommends Granting a Marketing Authorisation for Catumaxomab World News EMA Recommends Granting a Marketing Authorisation for Catumaxomab Από Ogkologos - 12 Νοεμβρίου, 2024 794 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR ESMO Breast Cancer Congress 2023 17 Απριλίου, 2023 Remembering With Gratitude 7 Ιανουαρίου, 2021 Reunión anual de la American Society of Clinical Oncology de 2023:... 6 Ιουνίου, 2023 NF1 Associated with More Cancer Types Than Previously Known 20 Απριλίου, 2021 Φόρτωση περισσοτέρων HOT NEWS Delayed irAEs Occur in a Small Subset of Patients with Melanoma,... Distinct and Overlapping Pathways Contribute to the Efficacy of Nivolumab-Based Regimens... Good-bye, Old Friend FDA Grants Accelerated Approval to Adagrasib with Cetuximab for KRAS G12C-mutated...